Standard radiation for medulloblastoma can cause long-term damage to a child’s developing brain. A new clinical trial suggests that the volume and dose of radiation could be safely tailored based on genetic features in the child’s tumor.
A new radiopharmaceutical drug (called 177Lu-PSMA-617) may be an option for treating advanced prostate cancer. In a large clinical trial, adding the drug to standard treatments improved how long participants lived.
Clinical Trials Information for Patients and Caregivers
Clinical trials are research studies that involve people. They are the vital and final step in the process of developing new treatments, screening and diagnostic tests, and prevention methods for cancer. This page can help people who want to learn more about what clinical trials are and why they are important.
Clinical trials can be confusing for people with cancer. This page offers questions that patients who are thinking about taking part in a cancer treatment clinical trial can ask their health care providers.
This phase 1 trial will test a combination of six drugs for people with B-cell lymphomas that have either come back or not responded to prior treatment. Doctors want to see if these drugs are safe and effective against B-cell lymphoma when given together.
This phase 3 trial will evaluate radiation therapy delivered in high doses over a shorter treatment period (hypofractionated) after surgery to remove a breast (mastectomy). Doctors want to see if adding radiation therapy will affect breast reconstruction and help prevent breast cancer from coming back.
This phase 1 trial will test the safety and tolerability of adding the experimental drug selinexor to the standard regimen of temozolomide (Temodar) and radiation therapy for people with glioblastoma. In laboratory studies, selinexor has been shown to enhance the sensitivity of glioblastoma cells to radiation. Doctors will also try to determine the maximum tolerated dose of selinexor when added to the standard treatment.
